Array Skin Therapy has opened its first Houston-area treatment centre near Katy, Texas, expanding access to medically supervised narrowband ultraviolet B phototherapy for patients with psoriasis, vitiligo, eczema and other eligible inflammatory skin conditions. Announced on October 27, 2026, the new facility is located at 11211 Katy Freeway, Suite 450, Houston, and forms part of the specialist dermatology service provider’s expanding US clinic network.
The opening extends a treatment model built around providing phototherapy outside traditional hospital-based or dermatology office settings. Array Skin Therapy specialises in delivering controlled ultraviolet light treatments through dedicated facilities, with the Houston clinic offering full-body booths, hand and foot equipment and targeted phototherapy systems. The additional capacity could improve local availability for patients whose conditions require repeated appointments over several weeks or months.
Unlike the introduction of a new medical device or pharmaceutical product, the Houston opening does not represent a novel clinical treatment or new regulatory authorisation. Narrowband UVB phototherapy is already an established dermatological intervention supported by professional guidelines for selected conditions. The commercial and clinical significance of Array Skin Therapy’s expansion therefore lies primarily in service accessibility, treatment delivery, patient adherence and the sustainability of a specialist outpatient care model.
How will Array Skin Therapy’s new Houston location expand access to established narrowband UVB phototherapy?
The new Houston/Katy clinic offers narrowband UVB treatment through equipment designed for different patterns of skin involvement. Full-body booths can accommodate patients with widespread disease, while smaller treatment units allow clinicians to focus on particular anatomical regions. This flexibility supports treatment planning for patients whose conditions vary in distribution, severity and response to previous therapies.
Array Skin Therapy said the location is intended to serve Houston, Katy and surrounding West Houston communities. The facility is led clinically by nurse practitioner Shir’mel McCullough, who serves as clinical director, alongside nurse practitioner Susan Nguy. Treatment plans are individualised according to diagnosis, skin type, medical history and the patient’s response to ultraviolet exposure.
The clinic is independently owned and operated by LTA Wellness PLLC, placing it within Array Skin Therapy’s broader expansion model without implying that every facility has identical ownership arrangements. The provider has established operations in Southern California and expanded into other markets, including Arizona and Utah. Houston represents its entry into another major metropolitan healthcare market where demand for convenient specialist services may support further network development.
The commercial opportunity is connected to the recurring nature of phototherapy rather than to a single high-value intervention. Patients often require a series of supervised treatments, making proximity, appointment availability and continuity of care important service characteristics. Whether the Houston clinic can convert local demand into sustained utilisation will depend on referral relationships, patient retention, scheduling capacity and payment arrangements.
Why does narrowband UVB light therapy remain relevant for psoriasis, vitiligo and eczema treatment?
Narrowband ultraviolet B phototherapy uses controlled ultraviolet radiation, generally concentrated around a wavelength of 311 to 313 nanometres, to produce therapeutic effects in affected skin. Its mechanisms differ across inflammatory and pigmentary diseases but include modulation of immune activity and changes in cellular behaviour. The treatment has an established role in dermatology, although clinical response depends on diagnosis, severity and individual patient characteristics.
For psoriasis, narrowband UVB can reduce excessive skin-cell proliferation and inflammatory activity associated with plaque formation. It is often considered when topical treatments provide insufficient control or when affected areas are too extensive for practical topical management alone. Professional guidelines recognise phototherapy as an option before certain systemic treatments or in selected combinations with other therapies.
In vitiligo, treatment aims to encourage repigmentation by influencing pigment-producing cells and local immune processes. Improvement may develop gradually, and anatomical location has a substantial effect on the likelihood of response. Facial and neck involvement often responds more favourably than areas such as fingertips and toes, making realistic expectations important during treatment planning.
For atopic dermatitis, or eczema, narrowband UVB may help reduce inflammation and persistent symptoms in selected patients. However, the evidence base for phototherapy in eczema is less robust than that for some other dermatological indications. The American Academy of Dermatology has issued a conditional recommendation for phototherapy in adults with atopic dermatitis, reflecting limitations in the available clinical evidence.
These differences mean that narrowband UVB should not be portrayed as equally effective for every skin condition or patient. The Houston clinic’s ability to deliver several types of phototherapy does not itself establish superior outcomes over other providers. Clinical value will depend on appropriate patient selection, individualised dosing and the quality of medical supervision.
Could specialist phototherapy clinics solve the appointment burden that limits long-term dermatology treatment adherence?
A persistent challenge with phototherapy is the requirement for repeated clinic visits. Depending on the condition and treatment protocol, patients may need sessions two or three times each week during an initial course. Individual exposures can be brief, but travel, waiting time and scheduling demands can make a course difficult to complete.
This operational burden creates a different type of access problem from the high acquisition cost associated with certain advanced dermatology medicines. Even when a treatment is clinically appropriate and covered by insurance, patients may struggle to attend enough sessions to obtain the intended benefit. Employment commitments, transportation limitations and distance from an established phototherapy facility can all affect adherence.
Dedicated outpatient clinics may address some of these barriers by expanding the number of locations where treatment is available. Array Skin Therapy’s model also separates phototherapy delivery from the broader responsibilities of a traditional dermatology practice, potentially allowing specialist staff and equipment to be organised around recurring treatment appointments. Whether that translates into shorter waiting times or higher treatment completion rates requires operational evidence rather than assumption.
The Houston clinic currently advertises weekday appointments from Monday through Thursday, with published operating hours of 8:30 a.m. to 4:30 p.m. Those hours establish an initial treatment schedule but may not accommodate every working patient’s requirements. Future appointment capacity, referral volume and patient demand will influence whether the facility’s operating model adequately addresses the practical barriers associated with frequent treatment.
How does the safety profile of narrowband UVB phototherapy compare with the perception of drug-free skin treatment?
Array Skin Therapy describes its services as drug-free, reflecting the use of therapeutic light rather than a medicine as the primary intervention. That distinction may appeal to patients seeking alternatives to systemic treatment, but drug-free should not be interpreted as risk-free. Narrowband UVB uses ultraviolet radiation and requires carefully controlled exposure to minimise unwanted effects.
Short-term adverse effects can include redness, skin irritation, dryness, itching and sunburn-like reactions. These risks are influenced by factors such as skin type, starting dose, treatment frequency and concurrent medication use. Appropriate supervision is intended to minimise avoidable exposure and adjust treatment according to the patient’s tolerance.
Professional phototherapy guidelines emphasise the importance of consistent clinical protocols, equipment maintenance and accurate ultraviolet dose measurement. The British Association of Dermatologists and British Photodermatology Group recommend appropriate initial exposure assessment and monitoring for adverse reactions. Equipment calibration and staff competency are therefore central to the quality of a phototherapy service.
Long-term cumulative ultraviolet exposure also requires consideration. Although narrowband UVB has a more favourable established safety profile than some older phototherapy approaches, uncertainties remain about lifetime exposure and skin cancer risk in particular patient groups. Guidelines recommend additional surveillance in patients with substantial cumulative treatment exposure, especially when other risk factors are present.
Patient suitability must be assessed individually, particularly when there is a history of skin cancer, a photosensitivity disorder or medication use that could alter ultraviolet sensitivity. The clinical team’s responsibility extends beyond operating treatment equipment to recognising contraindications and coordinating care where additional specialist assessment is required. This makes governance and clinical oversight important differentiators between a structured phototherapy service and unsupervised ultraviolet exposure.
What distinguishes Array Skin Therapy’s outpatient model from hospital phototherapy and home treatment options?
Dermatology practices and hospitals already offer phototherapy, while supervised home treatment is another established option for some patients. Array Skin Therapy is therefore entering a service-delivery market with existing alternatives rather than introducing an entirely new therapeutic category. Its proposed differentiation is based on specialised facilities, dedicated equipment and a network intended to improve convenient access.
Hospital-based services can offer integration with broader specialist care, including management of complex dermatological conditions. Home phototherapy may reduce travel requirements but introduces equipment, training, monitoring and reimbursement considerations. Dedicated outpatient clinics occupy an intermediate position by offering medically supervised treatment in facilities organised specifically around phototherapy delivery.
The Houston location’s equipment mix may support this model by accommodating both extensive and localised skin involvement. Full-body treatment booths and hand and foot systems allow different treatment areas to be addressed without requiring every patient to follow the same procedure. Targeted treatment capabilities may also help clinicians limit exposure to unaffected skin where clinically appropriate.
However, access to equipment alone does not demonstrate better outcomes. An independent evaluation would need to compare treatment completion, adverse events, patient satisfaction and clinical response against other delivery models. Array Skin Therapy has not presented comparative Houston-specific data establishing that its services outperform hospital clinics, dermatology practices or appropriately supervised home phototherapy.
How could insurance coverage and dermatologist referrals influence demand at the Houston phototherapy clinic?
Reimbursement is an important commercial consideration because phototherapy often requires multiple billable sessions rather than one appointment. Health insurance coverage may be available for eligible patients, but payment policies depend on the insurer, diagnosis, medical necessity and applicable benefits. Availability of an insurance billing pathway should not be mistaken for guaranteed coverage of every treatment course.
Prior authorisation requirements and patient cost-sharing can also influence access. Some insurers may require documentation of previous treatment response or other clinical information before covering phototherapy. Consequently, administrative support and clear financial communication can affect whether patients proceed with treatment after an initial consultation.
Array Skin Therapy said its Houston clinic welcomes both patients referred by dermatologists and individuals seeking a consultation directly. This approach could support two routes into the service, although eligibility for actual treatment remains a clinical decision. The ability to build relationships with local dermatology providers will be important because referring clinicians may retain responsibility for broader disease management.
Operational coordination will also matter where phototherapy is used alongside topical or systemic treatment. Referral information, medical history, treatment exposure records and progress updates should be managed consistently to avoid fragmented care. Successful integration into the local dermatology ecosystem could therefore be more commercially meaningful than simply increasing the number of available treatment booths.
What will determine whether Array Skin Therapy’s Houston expansion becomes a sustainable specialist care model?
Array Skin Therapy was founded in 2011 and has developed a network concentrated initially in Southern California before expanding into additional states. Its Houston opening demonstrates geographic expansion into Texas, but the announcement does not disclose clinic investment costs, treatment capacity, patient numbers or financial projections. Those omissions limit any attempt to quantify the immediate commercial contribution of the new location.
A specialised phototherapy clinic faces a capacity-management challenge because each treatment requires equipment access, staff oversight and an appropriate scheduling interval. Consistent utilisation can improve the economics of the service, while cancellations and incomplete treatment courses can affect productivity. The balance between appointment availability and clinically appropriate treatment frequency will influence operating efficiency.
Expansion through independently operated facilities may reduce the need for centralised ownership of every location, but it also creates requirements for consistent clinical standards. Training, quality assurance, equipment maintenance and patient experience must remain dependable across different operators. These factors become increasingly important as a healthcare service brand grows beyond its original regional market.
For patients and referring clinicians, the most relevant measures will be access, treatment completion and clinical outcomes rather than the pace of network expansion alone. A successful Houston operation would need to demonstrate that patients can obtain appropriate phototherapy without excessive scheduling or financial barriers. Consistent medical oversight and transparent management of ultraviolet exposure would be equally important.
The new clinic gives Array Skin Therapy a physical presence in a large metropolitan market while extending an established dermatology treatment through a specialist outpatient model. The underlying clinical evidence for narrowband UVB is well established in selected indications, but the performance of this particular location has yet to be measured. Its longer-term value will depend on whether greater local treatment availability leads to practical improvements in continuity of care and sustainable service delivery.
